-

Exact Sciences Schedules First Quarter 2024 Earnings Call

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

First quarter 2024 webcast & conference call details

Date:

 

Wednesday, May 8, 2024

Time:

 

5 p.m. ET

Webcast:

 

The live webcast can be accessed at www.exactsciences.com

Telephone:

 

Domestic callers, dial 888-330-2384

 

 

International callers, dial +1 240-789-2701

 

 

Access code for both domestic and international callers: 4437608

A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Contacts

Nathan Harrill
Exact Sciences Corp.
investorrelations@exactsciences.com
608-535-8659

Industry:

Exact Sciences Corp.

NASDAQ:EXAS
Release Versions
English

Contacts

Nathan Harrill
Exact Sciences Corp.
investorrelations@exactsciences.com
608-535-8659

More News From Exact Sciences Corp.

Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts across its Precision Oncology portfolio at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place from December 9-12 in San Antonio, Texas. The data to be presented builds upon Exact Sciences’ long-standing commitment to backing innovation with strong clinical evidence and commitment to equitable breast cancer care. This commitme...

Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome’s Blood-Based Colorectal Cancer Screening Tests

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) for its previously announced license agreement with Freenome. Under the agreement, the Company acquired exclusive rights in the United States to Freenome’s blood-based colorectal cancer (CRC) screening tests. The exclusive license expands Exact Sc...

Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced pivotal clinical validation results from the ALTUS study (NCT: 05064553). The prospective, head-to-head trial demonstrated that the company’s Oncoguard® Liver blood test delivers superior early-stage and overall sensitivity for hepatocellular carcinoma (HCC) — the most common form of liver cancer — compared to the current standard of care.1,2 These fi...
Back to Newsroom